Compounded vs. FDA-Approved GLP-1 Products

Direct answer

An FDA-approved GLP-1 drug and a compounded GLP-1 preparation are not the same regulatory category, even when they involve the same broadly named ingredient. FDA-approved drugs are reviewed by the U.S. Food and Drug Administration under an approved drug application for a specific product, formulation, strength, route, labeling, manufacturing process, and set of approved uses. Compounded drugs are not FDA-approved, and FDA does not review each compounded product for safety, effectiveness, or quality before it is marketed.

FDA approval applies to a specific product, not just an ingredient name

A common comparison mistake is to see the word “semaglutide” or “tirzepatide” and treat every offer using that ingredient name as the same product. That is not how RightFit models the market. An approved branded product is tied to an FDA-reviewed application and labeling. A compounded preparation is made for a patient under a different legal and regulatory framework. The ingredient name alone does not erase those differences.

That is why RightFit stores Wegovy, Ozempic, compounded semaglutide injections, compounded oral semaglutide formulations, Zepbound, Mounjaro, and compounded tirzepatide as distinct product or formulation records. A provider may advertise several of them at once. The fact that two offers sit in the same broad GLP-1 category does not make their prices directly interchangeable.

What FDA-approved means in a provider comparison

For a consumer comparison, FDA approval is not a badge that belongs to a telehealth company, a pharmacy, or an ingredient in the abstract. It describes a specific drug product that FDA has reviewed and approved. The approved product has prescribing information that identifies the active ingredient, dosage form, route of administration, warnings, contraindications, dosing information, storage requirements, and other product-specific details.

RightFit therefore tries to name the actual product whenever the provider does. If a provider advertises Wegovy, the comparison should say Wegovy rather than simply “semaglutide.” If it advertises a compounded semaglutide injection, the comparison should say that instead of borrowing the identity or approval status of a branded product. The same separation applies to tirzepatide products.

What compounded means

Drug compounding can serve legitimate patient needs, but it is not another route to FDA approval. FDA’s current consumer guidance says compounded drugs are not FDA-approved and do not undergo FDA’s premarket review for safety, effectiveness, or quality. FDA also recommends that compounded drugs be used when a patient’s medical needs cannot be met by an FDA-approved drug, and that patients obtain prescriptions from licensed prescribers and use state-licensed pharmacies.

A compounded product can also differ in ways that matter to a comparison: concentration, dosage form, route, inactive ingredients, packaging, vial size, instructions, pharmacy, and the amount supplied can vary. Those differences are one reason RightFit does not collapse all compounded products into one generic price row.

Compounded does not mean FDA-approved generic

The word “generic” has a specific meaning in the FDA approval system. FDA-approved generic drugs are reviewed and approved before marketing. FDA has specifically warned telehealth companies not to describe compounded drugs as generic versions of approved drugs or as the same as FDA-approved drugs. It has also warned against claims that a compounded product is FDA-approved or has been evaluated by FDA for safety and effectiveness when it has not.

RightFit applies that distinction to provider copy as well as its own. If a provider uses marketing shorthand that could blur the line between a compounded product and an approved brand, RightFit’s structured record should still identify the actual product category supported by the source rather than repeating the shorthand as a regulatory fact.

A pharmacy is not “FDA-approved”

FDA also cautions telehealth companies against saying compounded medication comes from an “FDA-approved” or “FDA-licensed” pharmacy or outsourcing facility. FDA does not approve or license pharmacies or outsourcing facilities. Depending on the facility and activity, state pharmacy regulators and federal requirements may both be relevant, but that is different from saying the pharmacy itself carries FDA approval.

For RightFit, pharmacy language belongs in a separate field from drug approval status. If a provider identifies the dispensing pharmacy, that can be recorded and sourced. It should not be converted into a claim that the compounded drug has FDA approval.

Compounding rules can change as supply and market conditions change

The rules that affect compounding are not frozen in time. FDA’s April 2026 clarification addressed conditions under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act and the restrictions involving products that are essentially copies of commercially available drugs. FDA stated at that time that semaglutide and tirzepatide were not on the 503B bulks list or the FDA drug shortage list.

Under the 503A framework described by FDA, a compounded product generally cannot be made regularly or in inordinate amounts as an essentially identical copy of a commercially available drug. FDA’s policy also describes circumstances in which a prescriber documents that a change produces a significant difference for an identified patient. Those details are one reason a broad statement such as “compounded GLP-1s are legal” or “compounded GLP-1s are banned” can be too simplistic without the date, product, pharmacy context, patient-specific prescription, and applicable compounding pathway.

Why telehealth marketing language deserves extra scrutiny

FDA has warned telehealth companies about false or misleading promotion of compounded drugs. Its examples include implying that a compounded drug is the same as an approved drug, calling it an FDA-approved generic, claiming FDA reviewed the compounded product for safety or effectiveness, or presenting the medication as coming from an FDA-approved or FDA-licensed pharmacy. FDA has also cautioned against claims that a compounded product is clinically proven to produce the same result as the approved drug.

This does not mean every telehealth company using the word “compounded” is making a prohibited claim. It means consumers should read the exact product description and RightFit should preserve the provider’s supported facts without upgrading marketing language into a stronger regulatory or clinical claim.

Formulation and dosing details matter too

Two offers can both say “compounded semaglutide” and still describe different concentrations, vial sizes, routes, dosing instructions, or combinations. FDA has raised concerns about dosing errors with compounded injectable semaglutide and tirzepatide, particularly when patients must measure doses from multi-dose vials or when units, milligrams, milliliters, and concentration are misunderstood.

FDA has also warned about semaglutide salt forms such as semaglutide sodium and semaglutide acetate, which it says are different active ingredients from the ingredient used in approved drugs and for which FDA is not aware of a lawful basis for use in compounding. RightFit therefore should not infer the exact active ingredient form from a broad provider headline when the source does not disclose it.

Why the distinction changes price comparisons

A low monthly price can be useful information, but only after identifying what the price buys. One price might cover an FDA-approved branded drug obtained through a cash-pay program. Another might cover a compounded medication bundled with clinical care. Another may be medication-only and require a separate membership. A fourth may be a monthly equivalent that is available only when several months are prepaid.

Comparing those numbers without the product identity and billing terms can create a false “cheapest” result. RightFit keeps medication amount, program fees, membership requirements, billing period, commitment, shipping, included care, formulation, and source date visible so a reader can decide whether two offers are actually comparable.

What to verify on a telehealth offer

• What exact medication, brand, or compounded formulation is being offered?
• Is the displayed price medication-only, or does it include clinical care, shipping, and required program fees?
• Is the rate billed monthly, prepaid for several months, or available only as an introductory offer?
• If the product is compounded, does the provider clearly identify it as compounded rather than FDA-approved or generic?
• Does the provider identify the dispensing pharmacy or pharmacy network without implying that the facility itself is FDA-approved?
• Are the concentration, route, supply amount, and dosing instructions clear enough to understand what is being purchased?
• Is the program available in the reader’s state, and can medication or pharmacy availability vary by state?
• When was the price or regulatory statement last verified?

What a consumer can ask before paying

A reader does not need to become a compounding-law expert to ask useful questions. Before paying, it is reasonable to ask the provider to identify the exact prescribed product, whether it is FDA-approved or compounded, which pharmacy will dispense it if prescribed, what amount is included, whether the pharmacy can change, what fees are separate, and what happens if the provider determines a different treatment is appropriate.

For compounded products, FDA advises patients to obtain a prescription through a licensed healthcare professional and fill it through a state-licensed pharmacy. If a medication arrives with unclear labeling, damaged packaging, questionable pharmacy information, or storage problems, the appropriate next step is to contact the prescriber, telehealth platform, or dispensing pharmacy rather than trying to resolve a quality concern from a comparison site.

How RightFit handles uncertainty

RightFit publishes a factual field only when the source supports it. If a provider page does not clearly identify the formulation, pharmacy, fee, state restriction, or billing term, the database should leave that field unverified rather than fill the gap with an assumption. If two current provider-owned pages conflict, the conflicting fact should stay in review until the discrepancy can be resolved.

That same rule applies to regulatory language. RightFit can report what FDA says, what a provider says it sells, and how the provider prices or structures the program. It should not turn those facts into an individualized medical judgment, declare a compounded product equivalent to an approved product, or imply that a lower price establishes a better treatment choice.

What this distinction does not decide

Regulatory category alone does not tell an individual which treatment is medically appropriate. FDA approval, compounding status, price, convenience, insurance access, route of administration, and provider support are different dimensions. A licensed healthcare professional should determine whether a medication is appropriate for a particular patient and, when compounding is considered, whether the patient-specific circumstances support that option.

RightFit’s role is narrower: identify the product accurately, keep approved brands and compounded formulations separate, preserve the source and verification date, and make the commercial terms easier to compare without turning an editorial comparison into medical advice.